Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Eur J Pharmacol. 2022 Oct 15;933:175272. doi: 10.1016/j.ejphar.2022.175272. Epub 2022 Sep 13.
To determine the role of β-adrenoceptor agonists on bladder sensory facilitation related to bladder myogenic contractile activities in bladder hyperactivity, we investigated the effects of vibegron, a β-adrenoceptor agonist, on the bladder and sensory function by evaluating cystometry and mechanosensitive single-unit afferent activities (SAAs), respectively, in a male rat model of bladder outlet obstruction (BOO). BOO was created by partial ligation of the urethra. Ten days after the surgical procedure, cystometric and SAA measurements were taken under two distinct conditions: a conscious-restrained condition, in which the bladder was constantly filled with saline, and a urethane-anesthetized condition involving an isovolumetric process with saline. For each measurement, vibegron (3 mg/kg) or its vehicle was administered intravenously after the data were reproducibly stable. In addition, the expression of β-adrenoceptor and substance P (SP), a sensory neuropeptide, in the bladder was further evaluated following immunohistochemical procedures. Number of non-voiding contractions (NVCs) in cystometry was decreased after vibegron-administration, which was a significant change from vehicle group. Number of microcontractions and SAAs of Aδ- and C-fibers were significantly decreased by vibegron-administration. Furthermore, β-adrenocepor and SP were co-expressed in the suburothelium layer of the bladder. These findings indicated that vibegron showed inhibitory effects on NVCs and microcontractions of the bladder, and SAAs of the Aδ- and C-fibers in BOO rats. The study suggested that vibegron can partly inhibit the mechanosensitive afferent transduction via Aδ- and C-fibers by suppressing bladder myogenic contractile activities in the rat bladder hyperactivity associated with BOO.
为了确定β-肾上腺素受体激动剂在膀胱过度活动相关的膀胱肌源性收缩活动引起的膀胱感觉易化中的作用,我们通过评估膀胱测压和机械敏感的单一单位传入活动(SAAs),分别研究了β-肾上腺素受体激动剂维贝格隆对膀胱和感觉功能的影响,在膀胱出口梗阻(BOO)的雄性大鼠模型中。通过尿道部分结扎来创建 BOO。在手术 10 天后,在两种不同条件下进行膀胱测压和 SAA 测量:在清醒约束条件下,膀胱持续用生理盐水填充;在麻醉状态下,使用生理盐水进行等容过程。对于每个测量,在数据稳定后静脉内给予维贝格隆(3mg/kg)或其载体。此外,还通过免疫组织化学程序进一步评估了膀胱中β-肾上腺素受体和感觉神经肽 P 物质(SP)的表达。膀胱测压中的非排尿收缩(NVC)数量在给予维贝格隆后减少,与载体组相比,这是一个显著的变化。微收缩的数量和 Aδ-和 C-纤维的 SAA 也被维贝格隆给药显著减少。此外,β-肾上腺素受体和 SP 在膀胱的下尿路层中共同表达。这些发现表明,维贝格隆在 BOO 大鼠中显示出对 NVC 和膀胱微收缩的抑制作用,以及 Aδ-和 C-纤维的 SAA。该研究表明,维贝格隆可以通过抑制与 BOO 相关的大鼠膀胱过度活动中的膀胱肌源性收缩活动,部分抑制通过 Aδ-和 C-纤维的机械敏感传入转导。